Home » The Viewpoint » Page 42

Category Archives: The Viewpoint

Ops Page for Editorials, and …Opinions

Cresemba / Isavuconazole:  Not Just Another Azole

Posted on by — No Comments ↓

It is amazing how modifications to the azole structure have produced ever more potent, ever more useful antifungals.  Ketoconazole had limited usability because of its many side effects related to off-target sterol synthesis inhibition, solubility (or lack thereof) and erratic absorption.  Solublity was also an issue for itraconazole and posaconazole.  Continue reading Cresemba / Isavuconazole:  Not Just Another Azole→

Artie’s Law: Avoid Bad Advice and Don’t Follow ‘Mission Impossible’ Advice

Posted on by — No Comments ↓

In this day and age, few truly broad spectrum antibiotics are in development, although this does not hold true for narrow-spectrums.  Just think of all the MRSA drugs (quinolones, FabI inhibitors), the pseudomonas drugs (NCEs and monoclonals) or some narrow spectrum drugs that will need to be tested in MDR Continue reading Artie’s Law: Avoid Bad Advice and Don’t Follow ‘Mission Impossible’ Advice→

Drugs with QIDP Designation – Update 4/8/2015

Posted on by — No Comments ↓

For the latest QIDP listing, please click HERE Our latest internet search came up with 37 drugs that garnered QIDP status.  They are listed in the Table below (if I missed a compound, please leave a comment!!).  The table is searchable so you should be able to massage the data to Continue reading Drugs with QIDP Designation – Update 4/8/2015→